NeuroOne Medical Technologies Corporation
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $1.9M | $2.9M | $2.7M | $1.7M | $1.4M | $3.3M | $272.3K |
| Cost of Revenue | $790.5K | $871.8K | $1.3M | $1.2M | $781.2K | $615.5K | $1.3M | $131.2K |
| Gross Profit | $1.2M | $990.3K | $1.6M | $1.5M | $914.8K | $771.1K | $1.9M | $141.1K |
| Gross Margin | 59.9% | 53.2% | 54.2% | 55.8% | 53.9% | 55.6% | 58.9% | 51.8% |
| Operating Expenses | ||||||||
| Research & Development | $1.4M | $1.5M | $1.4M | $1.1M | $1.2M | $1.5M | $1.2M | $1.1M |
| SG&A Expense | $2.2M | $1.9M | $1.9M | $1.8M | $1.6M | $1.9M | $2.0M | $1.8M |
| Operating Income | $-2.4M | $-2.4M | $-1.7M | $-1.4M | $-1.9M | $-2.7M | $1.7M | $-2.8M |
| Operating Margin | -122.9% | -128.7% | -59.0% | -50.0% | -111.2% | -193.3% | 52.3% | -1,034.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-2.0M | $-2.4M | $-1.4M | $-1.6M | $-1.5M | $-2.3M | $1.8M | $-3.4M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-2.0M | $-2.4M | $-1.4M | $-1.6M | $-1.5M | $-2.3M | $1.8M | $-3.4M |
| Net Margin | -101.7% | -127.9% | -49.7% | -59.1% | -88.5% | -163.8% | 54.5% | -1,230.6% |
| EPS (Basic) | $-0.23 | $-0.28 | $-0.03 | $0.48 | $-0.19 | $-0.44 | $0.06 | $-0.11 |
| EPS (Diluted) | $-0.28 | $-0.28 | $-0.03 | $0.48 | $-0.19 | $-0.44 | $0.06 | $-0.11 |
| Shares Outstanding (Basic) | 8.7M | 8.5M | 50.3M | 40.2M | 8.1M | 5.2M | 30.8M | 26.8M |
| Shares Outstanding (Diluted) | 8.7M | 8.5M | 50.3M | 40.2M | 8.1M | 5.2M | 30.9M | 26.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |